Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533902 | 1.00 | LMNA (0.44) | LMNAHSD17B10BTKKMT2ATSHR | |
| SCHEMBL25781445 | 0.87 | PTPN2 (0.40) | KMT2ATSHRMEN1ALDH1A1HRH3 | |
| SCHEMBL2082769 | 0.86 | ALDH1A1 (0.36) | KMT2ATSHRMEN1ALDH1A1HRH3 | |
| SCHEMBL2082768 | 0.86 | ALDH1A1 (0.36) | KMT2ATSHRMEN1ALDH1A1HRH3 | |
| SCHEMBL17574400 | 0.85 | MEN1 (0.36) | KMT2ATSHRMEN1ALDH1A1HRH3 | |
| SCHEMBL28403064 | 0.85 | MEN1 (0.36) | KMT2ATSHRMEN1ALDH1A1HRH3 | |
| SCHEMBL16439228 | 0.84 | CTSK (0.47) | BTKEPHX1 | |
| SCHEMBL7040763 | 0.83 | CTSK (0.38) | KMT2AMEN1HPGDSMN1; SMN2EPHX1 | |
| SCHEMBL7040760 | 0.83 | CTSK (0.38) | KMT2AMEN1HPGDSMN1; SMN2EPHX1 | |
| SCHEMBL23557801 | 0.83 | ALDH1A1 (0.34) | KMT2ATSHRMEN1ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-05 | — | — | US | disclosed |
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-29 | — | — | US | disclosed |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| EP-3056493-B1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| EP-2855452-B1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-9585881-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| EP-3056493-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9394250-B2 | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2855452-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174937-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD (JP) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | LMNA 834/4885HSD17B10 2216/4885BTK 262/4885 |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | LMNA 834/4885HSD17B10 2216/4885BTK 262/4885 |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | LMNA 834/4885HSD17B10 2216/4885BTK 262/4885 |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | LMNA 834/4885HSD17B10 2216/4885BTK 262/4885 |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | LMNA 834/4885HSD17B10 2216/4885BTK 262/4885 |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | LMNA 834/4885HSD17B10 2216/4885BTK 262/4885 |
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F10, F9 | LMNA 933/4885HSD17B10 2356/4885BTK 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.